Trial Profile
An Open Label Randomised Phase II Trial of RNActive Cancer Vaccine (CV9104) in High Risk and Intermediate Risk Patients With Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 21 Nov 2022
Price :
$35
*
At a glance
- Drugs CV 9104 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors CureVac
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 29 Apr 2016 Status changed from active, no longer recruiting to discontinued.
- 19 Jan 2016 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.